CLINICAL_TRIALS
trial_result
· 2024-07-31
Clinical Trial Update: Fycompa in Catamenial Epilepsy [Phase 4]
Summary
Phase 4 study of Fycompa (perampanel) for catamenial epilepsy was terminated, with results subsequently posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Florida | Conditions: Catamenial Epilepsy | Phase 4 | Status: TERMINATED | Results posted: 2024-07-31